Paratek Pharamceuticals jumps amid report about takeover interest

Paratek Pharmaceuticals (NASDAQ:PRTK) soared 22% amid a report about one of the potential private equity buyers for the biopharma company.
Gurnet Point Capital is said to be one of the PE firms circling the company, according to a Betaville "rare" alert.
The speculation comes after Betaville said in March that Paratek (PRTK) is a takeout target and that PE firms are the likely suitors.
Paratek's (PRTK) marketed products include the antibiotics Nuzyra (omadacycline) and Seysara (sarecycline).
Paratek (PRTK) reported Q1 results last month.